Royalty Report: Medical, Surgical, Device – Collection: 391188

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Medical
  • Surgical
  • Device
  • Drugs
  • Stem cells
  • implants
  • Injectibles
  • Orthopedic
  • Disease
  • Drug Discovery
  • cell therapy
  • Pharmaceuticals
  • Genome
  • Supply
  • Tissue
  • Cancer
  • Biotechnology
  • Test/Monitoring

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 391188

License Grant
The parties terminated the License, Supply and Operating Agreements and  eliminated Licensee’s membership interest in Licensor, and returned all in-process research and development assets to Licensee (the Development Assets). The agreement also provided indemnifications and complete releases by and among the parties.
License Property
Development Assets, limited to orthopedic product candidates developed using our biologics technology platform, including HST-003 and HST-004.

U.S. patents related to HST-003, HST-004, issued in the United States (U.S. Patent Nos. 8,530,415 and 9,512,403), which are also directed to the production of a tissue patch for the repair and regeneration of cells and methods of use using of extracellular matrix compositions and more specifically to proteins obtained by culturing cells under hypoxic conditions on microcarrier beads or a three-dimensional a surface in a suitable growth medium.

8,530,415 – Repair and/or regeneration of cells with a composition produced by culturing fibroblast cells under hypoxic conditions
9,512,403 – Conditioned medium and extracellular matrix compositions from cells cultured under hypoxic conditions for methods of treating tissue injury

HST-003 – for regenerating hyaline cartilage for the treatment of articular cartilage defects, consists of the following
• Physicians, and their patients, are seeking treatments that reverse cartilage degeneration.
• Less invasive procedures are preferred to preserve patient function and reduce surgical complications.
• Patients seek treatment options with shorter recovery periods and lasting treatment mechanisms that can promote more durable articular cartilage healing.
• Current treatment options fall into four key therapeutics categories, opioid, analgesic, cell/stem cell or disease modifying.
• Cartilage repair products currently on the market or in active clinical development include Collegium’s COL003, Adhera’s IT-102, Cytori’s adipose derived stem cells, Stempeucetics’ Stempeucel, Samumed’s SM-04690 and Medivir AB’s MIV-711.

HST-004 – for spinal disc repair treatment consists of the following
• Physicians, and their patients, are seeking treatments that reverse spinal disc degeneration after injury.
• Less invasive procedures are preferred to preserve patient function and reduce surgical complications that are common with such surgeries as spinal disc fusions.
• Patients seek treatment options when surgical procedures with fixation devices may not be clinically appropriate or earlier in the disease progression.  
• Current treatment options fall into four key therapeutics categories, opioid, analgesic, cell/stem cell or disease modifying.
• Spinal disc repair products currently in active clinical development include  autologous stem cell therapy (StemSpine, Novocart Disc, FibroGenesis), allogeneic cell therapy (Discogenics, Mallinkrodt) and a Wnt pathway inhibitor targeting CLK2/DYRK1A (Biosplice Therapeutics, formerly Samumed).

Field of Use
Field of use is for the treatment of articular cartilage defects and for spinal disc repair.

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.

IPSCIO Record ID: 28299

License Grant
The Licensor grants the Licensee an exclusive, worldwide right and license under the Licensed IP, to make, have made, use, sell, offer for sale, sublicense, have sold, import and have imported Licensed Products in Licensee and Licensor fields of use, and to modify and create derivatives for the treatment of spinal disorders.
License Property
The Licensor owns certain inventions, patents, patent applications, and other technical data and information for the treatment of spinal disorders.

“Licensed IF” means the Licensed Patents, Patent Applications and Inventions and all know-how, namely, technical information, manufacturing techniques and other intellectual property rights relating to the inventions covered by the Licensed Patents, and all other patents, patent applications, inventions or other intellectual property rights of Vertegen existing as of the date hereof that are required for ConforMIS’ exploitation of the licenses granted herein.

“ConforMIS Field of Use” means the diagnosis, assessment and treatment of articular disorders by the therapeutic use of Articular Repair Systems, including related current

“Articular Repair Systems” means any current or future devices or systems for the treatment of articular conditions or disorders, including without limitation implants made of metal, plastic, polymers, liquid metal or other suitable material; injectable solutions; self-expandable devices; inflatable devices; matrices and similar systems; hydrogels and similar systems; biological repair materials or kits; bio-resorbable materials or devices; surgical instruments; surgical planning techniques; and combinations of drugs and devices or combinations of different materials including biologies and non-biologics. “Articular Repair Systems” specifically excludes Spinal Repair Systems and the treatment of spinal disorders.

Title Devices and Methods for Treating Facet Joints,
Uncovertebral Joints, Costovertebral Joints and Other
Joints Serial No. 11/602,713

Title Devices and Methods for Treating Facet Joints,
Uncovertebral Joints, Costovertebral Joints and Other Joints
Application No. PCT/US2006/045131

Title U.S. Provisional Patent Application for Devices
and Methods for Treating Facet Joints, Uncovertebral Joints,
Costovertebral Joints and Other

Field of Use
Licensor field means the diagnosis, assessment, monitoring, surgical or interventional planning and treatment of spinal disorders by the therapeutic use of Spinal Repair Systems.
Licensee field means the diagnosis, assessment and treatment of articular disorders by the therapeutic use of Articular Repair Systems, including related current and future imaging techniques and other current and future approaches for implant sizing, shaping, selection, placement or manufacture.

IPSCIO Record ID: 2550

License Grant
The Company hereby grants a worldwide, non-exclusive, non-transferable, non-assignable, non-sublicensable  terminable license under the Intellectual Property that is the subject of Medtronic’s infringement, to make, have made, use, import, distribute, sell, have sold the Licensed Products incorporating or utilizing such Subject Technology within the Medtronic Area of Interest.
License Property
Medtronic Area of Interest means the areas of cardiovascular (excluding the tissue-engineered vascular grafts), endocrine, neurological, and spinal conditions or diseases.

A. ISSUED U.S. PATENTS
4,721,096   Process for Replicating Bone Marrow In Vitro and Using the Same
4,960,489   Three-Dimensional Cell and Tissue Culture System
5,032,508   Three-Dimensional Cell and Tissue Culture System
5,160,490   Three-Dimensional Cell and Tissue Culture System Apparatus
5,266,480   Three-Dimensional Skin Culture System
5,443,950   Three-Dimensional Cell and Tissue Culture System
5,460,939   Temporary Living Skin Replacement
5,478,739   Three-Dimensional Stromal Cell and Tissue Culture System
5,510,254   Three-Dimensional Cell and Tissue Culture System
5,512,475   Three-Dimensional Skin Cell and Tissue Culture System
5,516,680   Three-Dimensional Kidney Cell and Tissue Culture System
5,516,681   Three-Dimensional Pancreatic Cell and Tissue Culture System
5,518,915   Three-Dimensional Mucosal Cell and Tissue Culture System
5,541,107   Three-Dimensional Bone Marrow Cell and Tissue Culture System
5,559,022   Liver Reserve Cells
5,578,485   Three-Dimensional Blood-Brain Cell and Tissue Culture System
5,580,781   Three-Dimensional Tumor Cell and Tissue Culture System
5,599,788   Method for Accelerating Skin Wound Healing with H3 Protein
5,624,840   Three-Dimensional Liver Cell and Tissue Culture System
5,714,588   Enhancement of Cellular Attachment Using H3 Protein
5,763,267   Apparatus for the Large Scale Growth and Packaging of Cell
            Suspensions and Three-Dimensional Tissue Cultures
5,785,964   Three-Dimensional Genetically Engineered Cell and Tissue Culture
            System
5,792,603   Apparatus and Method for Sterilizing, Seeding, Culturing, Storing,
            Shipping and Testing Tissue, Synthetic or Native, Vascular Grafts
5,827,729   Diffusion Gradient Bioreactor and Extracorporeal Liver Device
            Using a Three-Dimensional Liver Tissue
5,830,708   Methods for Production of a Naturally Secreted Extracellular Matrix
5,842,477   Method for Preparing Cartilage
5,843,766   Apparatus for the Growth and Packaging of Three Dimensional
            Tissue Cultures
5,846,828   Apparatus and Method for Sterilizing, Seeding, Culturing,
            Storing, Shipping and Testing Tissue, Synthetic, or Mechanical
            Heart Valves or Valve Segments
5,849,588   Methods of Use of a Three-Dimensional Liver Cell and Tissue
            Culture System
5,858,721   Three-Dimensional Cell and Tissue Culture System
5,863,531   In Vitro Preparation of Tubular Tissue Structures by Stromal Cell
            Culture on a Three-Dimensional Framework
5,902,741   Three Dimensional Cartilage Cultures
5,919,702   Production of Cartilage Tissue Using Cells Isolated From
            Wharton's Jelly

5,928,945   Application of Shear Flow Stress to Chondrocytes or Chondrocytre
            Stem Cells to Produce Cartilage
5,962,325   Three-Dimensional Stromal Tissue Cultures
6,008,049   Diffusion Gradient Bioreactor and Extra-Corporeal Liver Device
6,022,743   Three-Dimensional Culture of Pancreatic Parenchymal Cells
            Cultured Living Stromal Tissue Prepared In Vitro
6,027,935   Gene Up-Regulated in Regenerating Liver
6,060,306   Apparatus and Method for Sterilizing, Seeding, Culturing, Storing,
            Shipping and Testing Replacement Cartilage Tissue Constructs
6,121,042   Apparatus and Method for Simulating In Vivo Conditions While
            Seeding And Culturing Three-Dimensional Tissue Constructs
6,140,039   Three-Dimensional Filamentous Tissue Having Tendon or Ligament
            Function
6,218,182   Method For Culturing Three-Dimensional Tissue in Diffusion
            Gradient Bioreactor and Use Thereof
6,284,284   Compositions and Methods for Production and Use of an Injectable
            Naturally Secreted Extracellular Matrix
6,291,240   Cells or Tissues With Increased Protein Factors and Method of
            Making Same

B. PENDING U.S. PATENT APPLICATIONS
08/488,165  Three-Dimensional Human Cell Cultures on Cardiac Valve Frameworks
            and Their Uses – on appeal
08/660,787  Compositions and Methods for Production and Use of an Injectable,
            Naturally Secreted Extracellular Matrix
09/256,649  Living Chimeric Skin Replacement
09/313,538  Conditioned Cell Culture Medium Compostions and Methods of Use
09/362,948  Genetically Engineered Cells Responsive to Environmental Cues
09/350,386  Human Naturally Secreted Extracellular Matrix-Coated Device and
            Methods for the Production and Uses Thereof
09/401,445  Three Dimensional Human Cell Cultures on Cardiac Valve Frameworks
            and Their Uses
09/411,585  Methods of Using a Three-Dimensional Stromal Tissue to Promote
            Angiogenesis
09/457,519  Application of Shear Flow Stress to Smooth Muscle Cells for the
            Production of Implantable Structures
09/482,203  Apparatus and Method for Sterilizing, Seeding, Cultiring, Storing,
            Shipping and Testing Tissue Synthetic or Native Vascular Grafts
09/603,642  Monitorable Three Dimensional Scaffolds and Tissue Culture
09/724,410  Cells or Tissues with Increased Protein Factors and Methods for
            Making Same
09/847,902  Container for Shipping Tissue
60/297,177  Compositions Comprising Conditioned Cell Culture Media and Uses
            Thereof

II. UNITED STATES PATENTS LICENSED TO ADVANCED TISSUE SCIENCES, INC.

A. LICENSED FROM THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY
4,418,691   Method of Promoting the Regeneration of Tissue at a Wound
4,458,678   Cell-Seeding Procedures Involving Fibrous Lattices
4,505,266   Method of Using a Fibrous Lattice
4,638,045   Non-Peptide Polyamino Acid Bioerodible Polymers
4,806,621   Biocompatible, Bioerodible, Hydrophobic, Implantable Polyamino
            Carbonate Article
4,947,840   Biodegradable Templates for the Regeneration of Tissues
5,041,138   Neomorphogenesis of Cartilage In Vivo From Cell Culture
5,128,420   Method of Making Hydroxamic Acid Polymers From Primary Amide
            Polymers
5,399,665   Biodegradable Polymers For Cell Transplantation
5,514,378   Biocompatible Polymer Membranes and Methods of Preparation of Three
            Dimensional Membrane Structures
5,516,532   Injectable Non-Immunogenic Cartilage and Bone Preparation
5,654,381   Functionalized Polyester Graft Copolymers
5,736,372   Biodegradable Synthetic Polymeric Fibrous Matrix Containing
            Chondrocyte For In Vivo Production of a Cartilaginous Structure
5,759,830   Three-Dimensional Fibrous Scaffold Containing Attached Cells for
            Producing Vascularized Tissue In Vivo
5,770,193   Preparation of Three-Dimensional Fibrous Scaffold For Attaching
            Cells to Produce Vascularized Tissue In Vivo
5,770,417   Three-Dimensional Fibrous Scaffold Containing Attached Cells for
            Producing vascularized Tissue In Vivo
5,804,178   Implantation of Cell-Matrix Structure Adjacent Mesentery, Omentum or
            Peritoneum Tissue
6,123,727   Tissue Engineered Tendons and Ligaments
6,095,148   Neuronal Stimulation Using Electrically Conducting Polymers
6,224,893   Semi-Interpenetrating or Interpenetrating Polymer Network for Drug
            Delivery and Tissue Engineering

B. LICENSED FROM THE UNIVERSITY OF FLORIDA
5,650,299   Cells Producing Stem Cell Proliferation Factor
5,981,708   Stem Cell Proliferation Factor

IPSCIO Record ID: 27776

License Grant
The Licensor grants the Licensee an exclusive, worldwide right and license under the Licensed IP, to make, have made, use, sell, offer for sale, sublicense, have sold, import and have imported Licensed Products in Licensee and Licensor fields of use, and to modify and create derivatives for the treatment of spinal disorders.
License Property
The Licensor owns certain inventions, patents, patent applications, and other technical data and information for the treatment of spinal disorders.

“Licensed IF” means the Licensed Patents, Patent Applications and Inventions and all know-how, namely, technical information, manufacturing techniques and other intellectual property rights relating to the inventions covered by the Licensed Patents, and all other patents, patent applications, inventions or other intellectual property rights

“ConforMIS Field of Use” means the diagnosis, assessment and treatment of articular disorders by the therapeutic use of Articular Repair Systems, including related current and future imaging techniques and other current and future approaches for implant sizing, shaping, selection, placement or manufacture.

“Articular Repair Systems” means any current or future devices or systems for the treatment of articular conditions or disorders, including without limitation implants made of metal, plastic, polymers, liquid metal or other suitable material; injectable solutions; self-expandable devices; inflatable devices; matrices and similar systems; hydrogels and similar systems; biological repair materials or kits; bio-resorbable materials or devices; surgical instruments; surgical planning techniques; and combinations of drugs and devices or combinations of different materials including biologies and non-biologics. “Articular Repair Systems” specifically excludes Spinal Repair Systems and the treatment of spinal disorders.

Title Devices and Methods for Treating Facet Joints,
Uncovertebral Joints, Costovertebral Joints and Other
Joints Serial No. 11/602,713
Filing Date November 21, 2006

Title Devices and Methods for Treating Facet Joints,
Uncovertebral Joints, Costovertebral Joints and Other Joints
Application No. PCT/US2006/045131
Filing Date November 21, 2006

Title U.S. Provisional Patent Application for Devices
and Methods for Treating Facet Joints, Uncovertebral Joints,
Costovertebral Joints and Other Joints
Serial No. 60/740,323

Field of Use
Licensor field means the diagnosis, assessment, monitoring, surgical or interventional planning and treatment of spinal disorders by the therapeutic use of Spinal Repair Systems.

Licensee field means the diagnosis, assessment and treatment of articular disorders by the therapeutic use of Articular Repair Systems, including related current and future imaging techniques and other current and future approaches for implant sizing, shaping, selection, placement or manufacture.

IPSCIO Record ID: 7008

License Grant
Licensor, a non-profit health care organization, hereby grants to Licensee the worldwide, sole exclusive License, including the right to grant subLicenses, under the Patent Rights and to practice the Licensed Processes.
License Property
This application generally relates to medical devices and more specifically relates to medical devices for use in the surgical treatment of hyperproliferative diseases affecting the spinal cord.
Field of Use
Field of Use shall mean treatment of Spinal cord injury.

IPSCIO Record ID: 273421

License Grant
The Parties reached a mutual understanding that the License Agreement drafted in 2001 no longer accurately reflected the business model of the Licensee, and that it contained certain restrictions and milestones that were not optimal for the commercialization of the Invention portfolio.

With this amendment, The University Regents grant a world-wide license under The Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Product and to practice Licensed Method in the Field.

License Property
This license is for certain inventions, generally characterized as Adipose-Derived Stem Cells and Lattices.

The patents include Isolation of Stromal Cells from Adipose Tissue, Isolation of Mesenchymal Stem Cells from Adipose Tissue, and, Adipose-Derived Stem Cells and Lattices.

Product means Research Product and Clinical Product.

Field of Use
The Field means any and all products and/or services for the research, diagnosis, and/or therapy of disease and/or disorders in humans and for cosmetic applications in humans.

Licensee is commercializing an automated device called Celution, which when operated in conjunction with various disposable component parts is capable of producing a heterogeneous isolate of the material naturally occurring in adipose tissue including unmodified amounts of stem cells and other regenerative cells, intended for human therapeutic, diagnostic, cosmetic and other uses.

The patented Celution® family of products process patients’ adipose-derived stem and regenerative cells (ADRCs) at the point of care. The Celution® family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation.  Licensee commercialization model is based on the sale of Celution® Systems and on generating recurring revenues from the single-use consumable sets.

Commercial activities are currently focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, where Cytori’s core product, the Celution® System, provides physicians with clinical grade stem and regenerative cells.

IPSCIO Record ID: 203392

License Grant
The University grants to Licensee a world-wide license under the Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method to the extent permitted by law.

The University also grants to Licensee the right to issue sublicenses to third parties to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method, as long as Licensee has current exclusive rights thereto under this Agreement, except that the sublicensee may not be granted the right to further sublicense the technology.

License Property
The technology and patents are for certain inventions, generally characterized as Connective Tissue Stem Cells.  The Cell Replacement Therapy means the use of adipose-derived stem cells for the therapeutic replacement of cells and tissues damaged by disease or injury.
Field of Use
The Field of Use means Cell Replacement Therapy in humans; Gene Therapy in humans; Cosmetic Surgery and Reconstructive Surgery in humans; Research and Collaboration Services; and the development and commercialization of Consumables.

IPSCIO Record ID: 369277

License Grant
Licensor, an university division of public health sciences, hereby grants to Licensee and Licensee accepts from Licensor, an exclusive, worldwide right and license, including the right to sublicense, to make, use and sell the Improvement Products under Licensors rights in the Improvement Patents in the Licensed Field only.

Licensor hereby grants to Licensee and Licensee accepts from Licensor, a non-exclusive, worldwide, right and license, including the right to sublicense, to the Know-How.

Licensor hereby grants to Licensee and Licensee accepts from Licensor for the Option Period (in each case) a non-transferable (except as specifically stated in Agreement), exclusive option to negotiate in good faith for a royalty-bearing, worldwide, exclusive license, including the right to sublicense, to practice all the rights under the New Development Patents in the Licensed Field only (the Option).

License Property
Patent Rights
6,673,339 – Prosthetic kidney and its use for treating kidney disease
6,576,019 – Bladder reconstruction
6,514,292 – Corporal tissue penile reconstruction
Field of Use
The agreement is in the field of regenerative medicine that will advance the development of organs and tissues to treat human diseases and disabilities.

The primary focus of the research will be on creating “neo-organs” and tissues. Neo-organs and tissues are derived from a patient’s own cells that are grown on a scaffold or model that is bioresorbable, or can be absorbed by the body. These neo-organs become functional replacements after being implanted in the patient’s body. Since they come from a patient’s own cells (autologous cells) there is virtually no risk of rejection from the body’s immune system.
In tissue engineering, neo-organ is a final structure of procedure based on transplantation of constructs consisting of endogenous stem/progenitor cells grown ex vivo within predesigned matrix scaffolds. The scaffold eventually is resorbed, leaving transplanted cells and the stroma that they produce in the body.

Licensed Field means human and animal organs, tissues and tissue-engineered and regenerative medicine products directed to their functions in the following areas (i) Genitourinary Tissue, (ii) Kidney Tissue, (iii) Cardiovascular Tissue, (iv) Nervous Tissue, and (v) Trachea Tissue. Each of Genitourinary Tissue, Kidney Tissue, Cardiovascular Tissue and Nervous Tissue is a Subfield.

Genitourinary Tissue means the reproductive system and the urinary system, including the male and female internal and external genitalia as well as all organs concerned in the formation and voidance of urine, but excluding Kidney Tissue. For the removal of doubt, Genitourinary Tissue is not to be considered Cardiovascular Tissue merely because it contains components of Cardiovascular Tissue.

Kidney Tissue means the kidney.

Cardiovascular Tissue means arteries, arterial tissue, veins and venous tissue. Cardiovascular Tissue does not include cardiac muscle tissue or heart valves.

Nervous Tissue means the (i) central nervous system, (ii) peripheral nervous system, and (iii) functional subcomponents and subunits of (i) and (ii) above. For the removal of doubt, a tissue or organ is not considered Nervous Tissue merely because it contains components of Nervous Tissue.

Trachea Tissue means the trachea and functional subcomponents and subunits thereof. Trachea Tissue does not include the bronchus and larynx.

IPSCIO Record ID: 114966

License Grant
A group of prominent spine surgeons agree to assist in the development of the Synergy Spinal System for royalty payments of any sales generated.
License Property
Synergy Spinal System is in the spinal implant product category and is used in spine fusion procedures.  The Synergy Spinal System consists of rods, hooks and screws that are attached to vertebrae adjacent to an injured or defective area of the spine. Our system is a 'universal' implant system that allows surgeonsto treat both the thoracic and lumbar portions of the spine.  The Synergy Spinal System does not require that surgeons follow a single surgical protocol, but provides several options, and can be used in both anterior and posterior applications, in both adults and children.  The Synergy Spinal System was designed to minimize the height and bulk of its implants, reducing the risk of irritation, inflammation and infection for the patient. It is consistently ranked as having one of the lowest profiles of commonly available spinal implant systems.
Field of Use
This agreement pertains to the medical device industry–spinal implants and orthobiologics.

IPSCIO Record ID: 7349

License Grant
The Licensee entered into a royalty Agreement with the Licensor and received the following assets from the Licensor
License Property
Certain patents and patent applications and all related active prosecution cases, trade secrets, know-how and certain other intellectual property rights, and all of the Licensor's goodwill with respect to the technology directly related to the research, development and commercialization of certain products and know-how related to hES cells;

Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);

Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensor’s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).

US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes

US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

Field of Use
The Licensee is a biotechnology company focused on the emerging field of regenerative medicine, with core technologies centered on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.

IPSCIO Record ID: 317633

License Grant
The Company and an executive of the Company entered into a Royalty Agreement wherein the Company agreed to pay the executive a royalty on a product-by-product basis for certain proprietary information and inventions that were patented during his employment with the Company.
License Property
Proprietary information and inventions include but not limited to the products such as Lucent Lateral Interbody Implant System, the Lucent XP Expandable Interbody Device System, the Clutch ISP Posterior Fixation System, the Karma Fixation System, the Vertu Anterior Stand-Alone System and Mosaic devices.

The product portfolio addresses a broad spectrum of spine surgery procedures and consists of innovative spinal fixation systems (implantable hardware systems that are mechanically attached to the spine and provide stability), interbody implants (devices implanted between the vertebral bodies of the spine), surgical instruments (instruments used to prepare the spine and implant our devices) and biologics (allograft or synthetic biomaterials intended to augment or replace the normal capacity of such tissue in the body).

“Product Line” shall mean each of the following product categories, with each understood to specifically contain and be solely composed of the individual products and parts set forth on Schedule A (i) Mosaic, (ii) Vertu, (iii) Lucent Lateral, (iv) Lucent Expandable, (v) ISP (Clutch), and (vi) Zip Tie (Karma).

Field of Use
The field of use is for the procedures used in surgery with reduced trauma to the muscles and soft tissues, less blood loss, smaller incisions, shorter procedure time, reduced hospitalization, lower post-operative medication use, faster patient recovery and other benefits for patients and surgeons.

The Company is a medical device company focused on the design, development and commercialization of a comprehensive portfolio of systems, products and technologies for spine surgery procedures, with a strategic focus on minimally invasive surgery (“MIS”) procedures.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.